FUSED PYRAZINE MONO-N-OXIDES AS BIOREDUCTIVE DRUGS .3. CHARACTERIZATION OF RB-90740 IN-VITRO AND IN-VIVO

被引:16
作者
NAYLOR, MA
ADAMS, GE
HAIGH, A
COLE, S
JENNER, T
ROBERTSON, N
SIEMANN, D
STEPHENS, MA
STRATFORD, IJ
机构
[1] MRC,DIV EXPTL ONCOL,RADIOBIOL UNIT,CHILTON OX11 0RD,ENGLAND
[2] UNIV ROCHESTER,CTR CANC,DIV TUMOR BIOL,ROCHESTER,NY 14642
基金
英国医学研究理事会;
关键词
BIOREDUCTIVE DRUGS; DNA STRAND BREAKS; HYPOXIA; N-OXIDES; REDUCTIVE ACTIVATION;
D O I
10.1097/00001813-199504000-00010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
RE 90740 is the lead compound in a series of aromatic mono-N-oxide bioreductive drugs. The compound shows considerably greater toxicity towards hypoxic verses aerobic mammalian cells in vitro. The differential in concentration required to give the same level of cell killing under these conditions ranges from 3.5 in a human bronchio-alveolar tumor cell line up to 120 in a rodent cell line defective in the repair of DNA strand breaks. The ability of RE 90740 to cause DNA strand breaks under hypoxic conditions was confirmed by alkaline sucrose gradient and pulsed field gel electrophoresis techniques. Despite these properties demonstrated in vitro, RE 90740 was shown not to be cytotoxic to hypoxic cells in experimental murine tumors in vivo. This may be due, in part, to the level of hypoxia (<0.02% O-2) necessary to produce toxicity in vitro.
引用
收藏
页码:259 / 269
页数:11
相关论文
共 49 条
[1]   BIOREDUCTIVE DRUGS AS POSTIRRADIATION SENSITIZERS - COMPARISON OF DUAL FUNCTION AGENTS WITH SR-4233 AND THE MITOMYCIN-C ANALOG-EO9 [J].
ADAMS, GE ;
STRATFORD, IJ ;
EDWARDS, HS ;
BREMNER, JCM ;
COLE, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (04) :717-720
[2]   BIOREDUCTIVE DRUGS FOR CANCER-THERAPY - THE SEARCH FOR TUMOR SPECIFICITY [J].
ADAMS, GE ;
STRATFORD, IJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (02) :231-238
[3]  
ADAMS GE, 1992, RAD RES 20TH CENTURY, V2, P802
[4]   CHEF ELECTROPHORESIS, A SENSITIVE TECHNIQUE FOR THE DETERMINATION OF DNA DOUBLE-STRAND BREAKS [J].
BLOCHER, D ;
EINSPENNER, M ;
ZAJACKOWSKI, J .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1989, 56 (04) :437-448
[5]   SR-4233 (TIRAPAZAMINE) - A NEW ANTICANCER DRUG EXPLOITING HYPOXIA IN SOLID TUMORS [J].
BROWN, JM .
BRITISH JOURNAL OF CANCER, 1993, 67 (06) :1163-1170
[6]  
BROWN JM, 1990, CANCER RES, V50, P7745
[7]  
CARMICHAEL J, 1987, CANCER RES, V47, P936
[8]   MEASUREMENT OF TUMOR HYPOXIA BY INVASIVE AND NONINVASIVE PROCEDURES - A REVIEW OF RECENT CLINICAL-STUDIES [J].
CHAPMAN, JD .
RADIOTHERAPY AND ONCOLOGY, 1991, 20 :13-19
[9]   ORAL (PO) DOSING WITH RSU-1069 OR RB-6145 MAINTAINS THEIR POTENCY AS HYPOXIC CELL RADIOSENSITIZERS AND CYTOTOXINS BUT REDUCES SYSTEMIC TOXICITY COMPARED WITH PARENTERAL (IP) ADMINISTRATION IN MICE [J].
COLE, S ;
STRATFORD, IJ ;
BOWLER, J ;
NOLAN, J ;
WRIGHT, EG ;
LORIMORE, SA ;
ADAMS, GE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (02) :387-395
[10]   DUAL FUNCTION NITROIMIDAZOLES LESS TOXIC THAN RSU 1069 - SELECTION OF CANDIDATE DRUGS FOR CLINICAL-TRIAL (RB 6145 AND OR PD 130908) [J].
COLE, S ;
STRATFORD, IJ ;
FIELDEN, EM ;
ADAMS, GE ;
LEOPOLD, W ;
ELLIOTT, W ;
SUTO, M ;
SEBOLTLEOPOLD, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (03) :545-548